Advanced Search

Technical Analysis for PHVS - Pharvaris N.V.

Grade Last Price % Change Price Change
F 22.75 2.11% 0.47
PHVS closed up 2.11 percent on Thursday, May 13, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical PHVS trend table...
Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
New 52 Week Low Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 2.11%
180 Bearish Setup Bearish Swing Setup 2.11%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.11%
Oversold Stochastic Weakness 2.11%
Outside Day Range Expansion -2.40%
Oversold Stochastic Weakness -2.40%
Older End-of-Day Signals for PHVS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 6 hours ago
Up 5% about 6 hours ago
Up 3% about 8 hours ago
60 Minute Opening Range Breakout about 9 hours ago
2x Volume Pace about 9 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators Basic chart:

Profile

  • Earnings date: ???
Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Health Sciences Rare Diseases Angioedema Hereditary Angioedema Complement Deficiency

Is PHVS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
May 12 Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer
May 6 What Type Of Shareholders Own The Most Number of Pharvaris B.V. (NASDAQ:PHVS) Shares?
Apr 29 Pharvaris EPS misses by $0.32
Apr 29 Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
Apr 21 Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
Apr 21 The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Mar 4 Pharvaris to Participate in BioCapital Europe
Mar 2 Pharvaris initiated neutral at BofA noting rivalry in addressable market
Feb 27 The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Feb 26 Pharvaris starts dosing in mid-stage PHVS416 hereditary angioedema study
See more PHVS news...

Indicators

Indicator Value
52 Week High 42.86
52 Week Low 20.87
Average Volume 54,764
200-Day Moving Average 0.00
50-Day Moving Average 27.60
20-Day Moving Average 24.42
10-Day Moving Average 23.61
Average True Range 2.28
ADX 24.79
+DI 13.73
-DI 26.26
Chandelier Exit (Long, 3 ATRs ) 23.45
Chandelier Exit (Short, 3 ATRs ) 27.70
Upper Bollinger Band 27.23
Lower Bollinger Band 21.61
Percent B (%b) 0.2
BandWidth 23.01
MACD Line -1.43
MACD Signal Line -1.37
MACD Histogram -0.0595
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.95
Resistance 3 (R3) 25.67 24.34 25.41
Resistance 2 (R2) 24.34 23.52 24.47 25.23
Resistance 1 (R1) 23.54 23.02 23.94 23.82 25.06
Pivot Point 22.21 22.21 22.41 22.34 22.21
Support 1 (S1) 21.41 21.39 21.81 21.69 20.44
Support 2 (S2) 20.08 20.89 20.21 20.27
Support 3 (S3) 19.28 20.08 20.09
Support 4 (S4) 19.56